• Fosun Pharma subsidiary Fosun Kairos initiated a Phase II trial of FKC516 injection in mainland China for relapsed/refractory B-cell non-Hodgkin lymphoma.
• The group holds exclusive global development and commercialization rights across all disease areas for the CD20-targeted autologous CAR-T cell therapy.
• Research and development investment totaled approximately RMB 13.37 million through September 2026, including license fees, on an unaudited basis.
• No CAR-T product targeting CD20 had been cleared for launch in mainland China as of November 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261112-12410009), on November 12, 2026, and is solely responsible for the information contained therein.